( MENAFN - GlobeNewsWire - Nasdaq) LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare conference at 10:55 am ET on November 19, 2024.

A webcast of the presentation will be available here beginning at 10:55 am ET on Monday, November 18, 2024 and will be posted on the Investors section of the Company’s website. About Krystal Biotech,

Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19,

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to partic

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.

Presentation Time: 3:00 p.m. ET Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology,

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, 8, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:35 a.

Monday, November 18, 2024 at 2:25 pm ET Location: New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of About Vor Bio Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.